ALK and lung adenocarcinoma: Although we focus on oncogenic EGFR-driven lung adenocarcinomas, our findings appear to extend to other molecular subsets such as EML4-ALK-driven lung cancer (Fig. 3l and Extended Data Fig. 6b–d) and likely reflect a more general principle of targeted therapy-induced adaptability.